Company research / LEXX

Lexaria Bioscience Corp. (LEXX)

CIK 0001348362 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NV
  • Fiscal year ends Aug 31

For the year ended 2025-08-31, Lexaria Bioscience Corp. reported revenue of $705.9K. Revenue grew 52.0% from the prior annual period.

Key ratios (year ended 2025-08-31)

99.6%
Gross margin
-1683.0%
Operating margin
-1686.0%
Net margin
-398.1%
Return on year-end equity
52.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 8-K · 2026-09-01

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.